A Rival to the Renal Denervation Therapy Procedure?
Vascular Dynamics is taking a different approach in its bid to treat patients with drug-resistant hypertension. While firms like Medtronic have gravitated toward using renal denervation to treat drug- resistant hypertension, Vascular Dynamics is developing a stent-like application to treat the condition, which effects more than 100 million patients in the U.S.
The Mountain View, CA-based company said it has enrolled the first patients in a pivotal trial. The companyâs CALM-2 study is designed to establish safety and efficacy of the endovascular baroreceptor amplification (EVBA) procedure using the MobiusHD device as a treatment for drug-resistant hypertension.
âThis is an endovascular neuro-receptor reflex activation device that is a permanent carotid stent-like implant,â Gregg Stone, MD, Co-Principal Investigator of the CALM-2 trial and Director of Cardiovascular Research and Education for NewYork-Presbyterian/Columbia University Medical Center and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation,toldMD+DI.
The CALM-2 trial is targeting enrollment of up to 300 patients at leading institutions across the U.S. and Europe.
â[The technology] has been used in a modest number of patients and open-label studies,â Stone said. âIt has been shown in patients with resistant hypertension to be quite remarkably effective. Now the question is...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
More News: Brain | Cardiology | Cardiovascular | Education | Heart | Hypertension | Learning | Medical Devices | Neurology | Reflex Sympathetic Dystrophy | Research | Study | Universities & Medical Training